



# 2025 Ovarian Cancer SPORE Developmental Research Program

## **Background**

HCC Ovarian Cancer Specialized Programs of Research Excellence (SPORE) supports a Developmental Research Program (DRP). The SPORE grant mechanism is aimed at translational research projects, defined by the NIH as:

Translational cancer research transforms scientific discoveries arising from laboratory, clinical, or population studies into clinical applications that reduce cancer incidence, morbidity, and mortality.

The goal of the DRP is to expand the pool of researchers committed to translational ovarian cancer research. Research initiatives that will be funded by the DRP are expected to have a major translational component focused on 1) prevention and early detection, 2) mechanisms of tumorigenesis and therapeutic resistance, 3) predictive and prognostic biomarkers, and 4) novel targets and approaches to therapy. The DRP provides a unique venue for developing cutting-edge new projects by providing significant financial support and active institutional commitment through a program that is rapidly responsive to new ideas or initiatives. These awards are intended to provide funding for collecting preliminary data and developing full projects to be considered for alternate peer-reviewed funding. Funded pilot projects that have the potential to be incorporated as a component of the HCC Ovarian Cancer SPORE are encouraged. Laboratory, clinical, epidemiological, and behavior-based projects emphasizing translational ovarian cancer research are all eligible for this award.

## **Funding**

The DRP will fund up to five awards for \$50,000 for one year, with the possibility of a one-year renewal for projects with highly promising results. Funds cannot be used for salary coverage of Principal or Co-Investigators, indirect costs, travel, publications, or equipment not specifically needed for the proposed research. Salary coverage for technicians, graduate students, or postdoctoral fellows is permitted.

Successful applicants must (i) attend and present their ongoing work at monthly Ovarian Cancer SPORE meetings and the Ovarian Cancer SPORE annual retreat and (ii) submit a final progress report at the end of the funding period.

A second year of funding will be considered for applicants with an extremely productive initial year.

# **Eligibility**

- Full-time Faculty Member, Associate Professor level or higher
- Full-time Faculty Member, Assistant Professor with current or past R01-type grant award

#### **Deadlines**

Full proposals, including all documents listed below, are due June 9, 2025, at 5:00 pm ET. Late submissions will not be accepted.





#### **Format**

Applicants must adhere to a modified NIH R21 format; required documents and page length are provided in the **Cover Page Checklist** below. For applicants outside of the University of Pittsburgh, a letter of institutional commitment of matching funds (\$25,000 per year funded) is required

All data critical to review must be included in the proposal text. No Appendices are allowed.

### **Review Criteria**

All applications will be reviewed by scientific investigators and patient advocates using a modified NIH research project review criteria and the NIH scoring system (1-9). These criteria include:

Significance

- Investigator and Team
- Innovation

Approach

- Translational Potential
- Potential to produce definitive results within the proposed time frame
- Potential to advance to a SPORE Individual Research Project or R01-type funding

#### Resubmissions

Previously submitted applications that did not receive a fundable score are eligible for funding consideration. Resubmissions must include a 1-page response to previous reviewer comments and indicate the application as a resubmission on the cover page.

#### Renewals

Previously funded DRPs are eligible for renewal. However, the program's priority is to fund new applications. DRP recipients who are considering a renewal application are encouraged to contact the DRP scientific contacts to discuss the likelihood of success of an additional year of funding. Renewal submissions must include a 2-page progress report and indicate the application as a renewal on the cover page.

#### Questions

For scientific questions, please contact:

Dr. Francesmary Modugno (modugnof@upmc.edu)

Dr. Katherine Aird (katherine.aird@pitt.edu)

For administrative questions, please contact: Cait Kelly (kellyc23@upmc.edu)

### Timeline for the HCC Ovarian Cancer DRP (dates tentative and subject to change)

06/09/2025 **5pm ET Full proposals due** – *late submissions will NOT be accepted*07/15/2025 Applicant notifications
09/01/2025 Budget start date

10/01/2026 Final project report due

10/15/2026 Present results to SPORE IAB/EAB





# **Cover Page and Checklist**

Part A: Applicant information	
Principal Investigator:	
Faculty Title:	
Department:	Email address:
Co-Investigators	Department & Email address
PROJECT TITLE (80-character limit)	
Resubmission? YES NO	
Funding requested \$	
Part B: IRB / IACUC Approvals Include approval documentation as appropriate.	
<b>IRB</b>	ate: NO PENDING
	ate: NO PENDING
Is there anyone who would have a conflict of interest if they were asked to review this proposal?	
If yes, please provide list of names on separate page (not included in page limits)	
David C. Di Sianachiya and data	
Part C: PI Signature and date	
Part D: Checklist of required documents	
•	
Cover Page	(must use provided cover page)
Response to Reviewers (for resubmission applications only)(1-page max)	
Specific Aims (1-page max)	
☐ Translational Potential (1/2 page max) ☐ Research Plan (3-page max)	
References Cited (no page limit)	
Timeline and Milestones (1 page max)	
PI's Biosketch (NIH Format)	
Other Support (verified by applicant's fiscal office) (PHS 398)	
Letter of Institutional matching funds (non-Pitt applicants only) (1-page max)	
Biosketches for co-investigators – OPTIONAL	
☐ Budget <u>and Justification</u> (2-page max)☐ If human subjects or animals are involved, include IRB/IACUC approval letter or submission date	
NO APPENDICES ARE PERMITTED	